Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 29, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On July 28, 2003, Abacus (GSK) Trustees Limited transferred 5,913 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Key Facts for Investor Verification
- 5,913 Ordinary Shares were transferred from the GSK Trust to employee plan participants on July 28, 2003.
- Directors Dr. J-P Garnier and Mr. J D Coombe have an indirect interest in the GSK Trust shares alongside other employees.
- This filing contains no financial performance metrics or operational guidance.